Target intelligence / Profile preview

Complement C1q subcomponent subunit C (C1QC)

Target
C1QC
Molecular classification
Pattern recognition molecule (PRM), Subunit of complement protein, Non-enzymatic structural protein
01

Overview

Complement C1q subcomponent subunit C (C1QC) is one of the three polypeptide chains (A, B, and C) that form the C1q molecule of the complement system, a core component of the classical complement pathway. C1q is assembled from six heterotrimers (each containing C1qA, C1qB, and C1qC), resulting in a hexameric bouquet-shaped protein. The C1q C chain contains both an N-terminal collagen-like domain and a C-terminal globular recognition domain. The entire C1q molecule recognizes pathogens, apoptotic cells, and immune complexes and subsequently triggers complement activation by interacting with C1r and C1s proteases. Deficiency or dysfunction of C1q—including its C subunit—is strongly associated with immune diseases such as SLE and can also affect angiogenesis, neurodevelopment, and cancer progression. Therapeutic targeting of C1q or its subunits is under investigation for immunomodulation and complement-related disorders, with C1q levels also serving as clinical biomarkers.

Other names
C1QCComplement C1q subcomponent CComplement C1q subcomponent subunit CComplement component 1 q subcomponent, gamma polypeptideC1Q-CC1QGC1QD3
02

Mechanism of action

For research/therapeutics targeting C1q/C1QC: inhibition of classical complement activation, modulation of immune recognition and phagocytosis, blockade of interaction with immune complexes or cell surface receptors

03

Biological functions

Initiation of the classical complement pathwayRecognition and opsonization of immune complexesClearance of apoptotic cells and cellular debrisRegulation of immune cell functionModulation of angiogenesis, inflammation, and cancer biology
04

Disease associations

Systemic lupus erythematosus (SLE)GlomerulonephritisInfectionsNeurodegenerative diseasesCancer (tumor angiogenesis)Cardiovascular diseasesInflammatory disorders
05

Safety considerations

Broad complement inhibition may compromise host defense against infectionPossible off-target effects on angiogenesis, neuroprotection, and tissue homeostasis
06

Interacting drugs

No approved small-molecule drugs directly targeting C1QC; experimental biologics (e.g., monoclonal antibodies) and inhibitors of complement activation may affect C1q function
07

Biomarkers

Serum C1q (including C1QC expression) as a biomarker for SLE and monitoring complement activationLow C1q levels in genetic deficiency states or SLE

Beyond the preview

Go deeper on Complement C1q subcomponent subunit C (C1QC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Complement C1q subcomponent subunit C (C1QC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call